{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:38Z","timestamp":1786118978398,"version":"build-2736575974"},"reference-count":53,"publisher":"Informa UK Limited","issue":"8-9","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioanalysis"],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.1080\/17576180.2026.2693653","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:47:27Z","timestamp":1785145647000},"page":"735-750","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of abatacept mediated immunogenicity using domain-specific and neutralizing antibody assays: a biosimilar perspective"],"prefix":"10.1080","volume":"18","author":[{"given":"Kamala","family":"Bhavaraju","sequence":"first","affiliation":[{"name":"Dr. Reddy\u2019s Laboratories Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi Dhananjaya","family":"Jakhade","sequence":"additional","affiliation":[{"name":"Dr. Reddy\u2019s Laboratories Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Kasinath","sequence":"additional","affiliation":[{"name":"Syngene International Limited","place":["Bangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00873-8"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.53555\/jptcp.v29i04.5810"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.03.001"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221309788489805"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013496"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02650-8"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyad029"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2xjg0d"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111531"},{"key":"e_1_3_7_12_1","unstructured":"European Medicines Agency. Orencia\u00ae: EPAR \u2013 product information. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orencia-epar-product-information_en.pdf"},{"issue":"11","key":"e_1_3_7_13_1","first-page":"22","article-title":"A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein","volume":"17","author":"Rosenberg A","year":"2004","unstructured":"Rosenberg A, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein. BioPharm Int. 2004;17(11):22\u201326.","journal-title":"BioPharm Int"},{"issue":"12","key":"e_1_3_7_14_1","first-page":"34","article-title":"A risk-based approach to immunogenicity concerns of therapeutic protein products: part 2. Considering host-specific and product-specific factors impacting immunogenicity","volume":"17","author":"Rosenberg AS","year":"2004","unstructured":"Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products: part 2. Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int. 2004;17(12):34\u201342.","journal-title":"BioPharm Int"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.020"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.01.001"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21876"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007277.pub2"},{"key":"e_1_3_7_19_1","unstructured":"FDA. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection. Guidance for industry. 2019. Available from: https:\/\/www.fda.gov\/media\/119788\/download"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel066"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00649-y"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01197-5"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2019-0283"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00830-5"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01030-z"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2024.2376949"},{"key":"e_1_3_7_27_1","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-herapeutic-proteins-revision-1_en.pdf"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.018"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9599-2"},{"key":"e_1_3_7_30_1","volume-title":"Presented At: EMA Workshop Immunogenicity","author":"Wakshull E","year":"2016","unstructured":"Wakshull E. Target\/Drug interference considerations. Presented At: EMA Workshop Immunogenicity; London, UK; 2016."},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0347-5"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-4974"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00447-y"},{"key":"e_1_3_7_34_1","volume-title":"Presented At: EMA Workshop Immunogenicity Assess Biotechnology Derived Therapeutic Proteins","author":"Gupta S","year":"2016","unstructured":"Gupta S. Neutralising assay methodologies. Presented At: EMA Workshop Immunogenicity Assess Biotechnology Derived Therapeutic Proteins; Amsterdam, Netherlands; 2016."},{"key":"e_1_3_7_35_1","unstructured":"Aranda R Dodge R Gleason CR et al. Methods related to CTLA4-Fc fusion proteins and immunogenicity characterization. US patent 10 450 361 B2. 2019 Oct 22."},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.06.002"},{"key":"e_1_3_7_37_1","volume-title":"European Bioanalysis Forum (EBF) Immunogenicity Workshop","author":"Liang M","year":"2021","unstructured":"Liang M. Domain specificity of immunogenicity assessment for multi-domain biotherapeutics. In: European Bioanalysis Forum (EBF) Immunogenicity Workshop. EBF. 2021."},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00806-5"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0107-3"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1048411"},{"key":"e_1_3_7_41_1","volume-title":"Strategies for improving ADA assay sensitivity","author":"Munday J","year":"2016","unstructured":"Munday J. Strategies for improving ADA assay sensitivity. Lisbon, Portugal: EBF Immunogenicity Workshop; 2016."},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.95"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0148-7"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7643-8550-7_20"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2011.08.002"},{"key":"e_1_3_7_46_1","volume-title":"Strategy for selecting NAb assay format","author":"McNally J","year":"2016","unstructured":"McNally J. Strategy for selecting NAb assay format. Lisbon, Portugal: European Bioanalysis Forum; 2016."},{"key":"e_1_3_7_47_1","unstructured":"Sword Bio. Nab assays for therapeutic proteins: addressing common pitfalls and solutions. Available from: https:\/\/swordbio.com\/blog\/nab-assays-for-therapeutic-proteins-addressing-common-pitfalls-and-solutions\/"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780203026427-15"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130263"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080002"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.070280"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2014.05.010"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080359"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101121"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.03.038"}],"container-title":["Bioanalysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2693653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17576180.2026.2693653","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17576180.2026.2693653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:07Z","timestamp":1786036387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17576180.2026.2693653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":53,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2026,6,13]]}},"alternative-id":["10.1080\/17576180.2026.2693653"],"URL":"https:\/\/doi.org\/10.1080\/17576180.2026.2693653","relation":{},"ISSN":["1757-6180","1757-6199"],"issn-type":[{"value":"1757-6180","type":"print"},{"value":"1757-6199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ibio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}